The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...
Is the era of sourcing cheaper weight loss drugs from the internet over? High demand for GLP-1 agonists — prescription drugs ...
Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...
Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could ...
NanoPortalâ„¢ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose ...
Step right up, ladies and gentlemen, and welcome to the hottest new spot in town: The Weight-Loss Casino! Here, you don’t ...
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Patients who received semaglutide before MBS from 2017 to 2024 were matched 1:1 with patients who did not receive semaglutide before MBS using nearest-neighbor propensity score matching.